Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 437

Showing 1-25 of 437 citing articles:

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 571
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 569
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 376
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 361
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 361
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 352
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 259
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2021) Vol. 71, Iss. 4, pp. 778-788
Open Access | Times Cited: 245
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 217
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 214
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 165
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160
Metabolic drivers of non-alcoholic fatty liver disease
Kendra K. Bence, Morris J. Birnbaum
Molecular Metabolism (2020) Vol. 50, pp. 101143-101143
Open Access | Times Cited: 153
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development
Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella
Nutrients (2021) Vol. 13, Iss. 5, pp. 1442-1442
Open Access | Times Cited: 138
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 117
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 92
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Narjes Nasiri‐Ansari, Θεόδωρος Ανδρουτσάκος, Christina‐Maria Flessa, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2511-2511
Open Access | Times Cited: 75
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
Federico Ravaioli, Elton Dajti, Alessandro Mantovani, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1399-1409
Closed Access | Times Cited: 49
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Pegah Golabi, James M. Paik, Ameeta Ravi Kumar, et al.
Metabolism (2023) Vol. 146, pp. 155642-155642
Closed Access | Times Cited: 43
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Michael Cooreman, Javed Butler, Robert P. Giugliano, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 20
Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
Matheus Souza, Marcio J. M. Amaral, Luan C. V. Lima, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 129
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros
Metabolism (2020) Vol. 111, pp. 154320-154320
Open Access | Times Cited: 121
Page 1 - Next Page

Scroll to top